Morgan Stanley analyst Judah Frommer initiates coverage on $Bicara Therapeutics (BCAX.US)$ with a buy rating, and sets the target price at $35.
According to TipRanks data, the analyst has a success rate of 48.4% and a total average return of -3.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Bicara Therapeutics (BCAX.US)$'s main analysts recently are as follows:
Early clinical findings for ficerafusp alfa indicate a significant potential improvement over existing standard of care treatments in recurrent/metastatic head and neck cancer. As further data is anticipated in 2027, comparative valuation with Bicara Therapeutics' main competitor provides a supportive backdrop for the company's prospects.
Bicara Therapeutics has shown promising results from a Phase 1b dose-expansion trial that assessed the combination of ficerafusp alfa and pembrolizumab in treating first-line metastatic squamous cell carcinoma of the head and neck, with the outcomes potentially setting a new industry standard. It is suggested that the current market valuation may not fully account for the significant potential of the drug becoming a standard treatment in a solid tumor market worth several billion dollars.
The treatment landscape for head and neck cancer, which has been historically underdeveloped, is expected to be significantly transformed by a new class of next-generation epidermal growth factor receptor bispecifics. The depth and durability of ficerafusp alfa's response in the first-line setting positions the company advantageously as the pivotal program commences. The market for first-line head and neck squamous cell carcinoma could represent a $5B-$10B opportunity, and ficerafusp alfa is seen as having a very high probability of successful development.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.